Top

International Journal of Clinical Pharmacy

Published in:

01-10-2009 | Commentary

Current issues around the pharmacotherapy of ADHD in children and adults

Authors: Willemijn M. Meijer, Adrianne Faber, Els van den Ban, Hilde Tobi

Published in: International Journal of Clinical Pharmacy | Issue 5/2009

Abstract

Background New drugs and new formulations enter the growing market for ADHD medication. The growing awareness of possible persistence of ADHD impairment beyond childhood and adolescence resulting in increased pharmacotherapy of ADHD in adults, is also a good reason for making an inventory of the what is generally known about pharmacotherapy in ADHD. Aim To discuss current issues in the possible pharmacotherapy treatment of ADHD in children, adolescents and adults with respect to the position of pharmacotherapy in ADHD treatment guidelines, the pharmacoepidemiological trends, and current concerns about the drugs used. Methods A search of the literature with an emphasis on the position of pharmacotherapy in ADHD treatment guidelines, the pharmacoepidemiological trends, and current concerns about the drugs used in pharmacotherapy. Results According to the guidelines, the treatment of ADHD in children consists of psychosocial interventions in combination with pharmacotherapy when needed. Stimulants are the first-choice drugs in the pharmacological treatment of ADHD in children despite a number of well known and frequently reported side effects like sleep disorders and loss of appetite. With regard to the treatment of adults, stimulant treatment was recommended as the first-choice pharmacotherapy in the single guideline available. Both in children and adults, there appears to be an additional though limited role for the nonadrenergic drug atomoxetine. The increase of ADHD medication use, in children, adolescents and in adults, can not only be interpreted as a sign of overdiagnosis of ADHD. Despite the frequent use of stimulants, there is still a lack of clarity on the effects of long-term use on growth and nutritional status of children. Cardiovascular effects of both stimulants and atomoxetine are rare but can be severe. The literature suggests that atomoxetine may be associated with suicidal ideation in children. Conclusion Although pharmacotherapy is increasing common in the treatment of ADHD in both children and adults, there are still a lot of questions about side effects and how best to counter them. This suggests an important role for close monitoring of children and adults treated with stimulants or atomoxetine.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Author: American Psychiatric Association; 1994.

Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. J Am Med Assoc. 1998;279(14):1100–7. doi:10.1001/jama.279.14.1100.CrossRef

Mental Health in the United States. Prevalence of diagnosis, medication treatment for attention-deficit/hyperactivity disorder––United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;4(34):842–7.

Barkley R. Attention-deficit hyperactivity disorder. A handbook for diagnosis and treatment. 3rd ed. New York: The Guilford Press; 2006.

Bren L. ADHD: not just for kids anymore. FDA Consum. 2004;38(6):14–20.PubMed

Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ. 2003;168(6):715–22.PubMedPubMedCentral

Wender PH, Wolf LE, Wasserstein J. Adults with ADHD. An overview. Ann N Y Acad Sci. 2001;931:1–16.CrossRefPubMed

Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry. 2005;57(11):1442–51. doi:10.1016/j.biopsych.2005.04.001.CrossRefPubMedPubMedCentral

Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry. 2000;39(11):1424–31. doi:10.1097/00004583-200011000-00017.CrossRefPubMed

10.

Riccio CA, Wolfe M, Davis B, Romine C, George C, Lee D. Attention deficit hyperactivity disorder: manifestation in adulthood. Arch Clin Neuropsychol. 2005;20(2):249–69. doi:10.1016/j.acn.2004.07.005.CrossRefPubMed

11.

Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816–8. doi:10.1176/appi.ajp.157.5.816.CrossRefPubMed

12.

de Graaf R, Kessler RC, Fayyad J, Ten Have M, Alonso J, Angermeyer M, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008;65:835–42.CrossRefPubMedPubMedCentral

13.

Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9. doi:10.1192/bjp.bp.106.034389.CrossRefPubMed

14.

Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23. doi:10.1176/appi.ajp.163.4.716.CrossRefPubMedPubMedCentral

15.

Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP. Internal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adults. Psychol Med. 2005;35(6):817–27. doi:10.1017/S003329170400337X.CrossRefPubMed

16.

Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD). NIH Consens Statement. 1998;16(2):1–37.

17.

American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105(5):1158–70. doi:10.1542/peds.105.5.1158.CrossRef

18.

American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033–44. doi:10.1542/peds.108.4.1033.CrossRef

19.

Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I7–30. doi:10.1007/s00787-004-1002-x.PubMed

20.

Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14(1):11–28. doi:10.1016/S0924-977X(03)00045-2.CrossRefPubMed

21.

Multidisciplinaire richtlijn ADHD: richtlijn voor de diagnostiek en behandeling van ADHD bij kinderen en jeugdigen. Utrecht: Trimbos-instituut. 2005.

22.

Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409–32. doi:10.1097/00004583-199604000-00008.CrossRefPubMed

23.

Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165(11):1475–88.PubMedPubMedCentral

24.

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073–86. doi:10.1001/archpsyc.56.12.1073.CrossRef

25.

National Institute of Mental Health. Multimodal treatment study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754–61. doi:10.1542/peds.113.4.754.CrossRef

26.

Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, et al. 3-Year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46(8):989–1002. doi:10.1097/CHI.0b013e3180686d48.CrossRefPubMed

27.

Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165(6):721–30. doi:10.1176/appi.ajp.2007.05091676.CrossRefPubMed

28.

Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21(1):10–41. doi:10.1177/0269881106073219.CrossRefPubMed

29.

Wilens TE. Drug therapy for adults with attention-deficit hyperactivity disorder. Drugs. 2003;63(22):2395–411. doi:10.2165/00003495-200363220-00002.CrossRefPubMed

30.

Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98(6 Pt 1):1084–8.PubMed

31.

Zito JM, Safer DJ, Dos Reis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. J Am Med Assoc. 2000;283(8):1025–30. doi:10.1001/jama.283.8.1025.CrossRef

32.

Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT. Psychotropic medication in children: a study from the Netherlands. Pediatrics. 2001;108(2):E25. doi:10.1542/peds.108.2.e25.

33.

Miller AR, Lalonde CE, McGrail KM, Armstrong RW. Prescription of methylphenidate to children and youth, 1990–1996. CMAJ. 2001;165(11):1489–94.PubMedPubMedCentral

34.

Reid R, Hakendorf P, Prosser B. Use of psychostimulant medication for ADHD in South Australia. J Am Acad Child Adolesc Psychiatry. 2002;41(8):906–13. doi:10.1097/00004583-200208000-00008.CrossRefPubMed

35.

Zito JM, Safer DJ, Dos Reis S, Gardner JF, Magder L, Soeken K, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003;157(1):17–25.CrossRefPubMed

36.

Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord. 2007;10(4):335–42. doi:10.1177/1087054707299597.CrossRefPubMed

37.

Faber A, den Berg LT, van den Berg PB, Tobi H. Psychotropic co-medication among stimulant-treated children in the Netherlands. J Child Adolesc Psychopharmacol. 2005;15(1):38–43. doi:10.1089/cap.2005.15.38.CrossRefPubMed

38.

Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995–2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol. 2004;60(5):377–9. doi:10.1007/s00228-004-0765-9.CrossRefPubMed

39.

Coghill D. Use of stimulants for attention deficit hyperactivity disorder: FOR. BMJ. 2004;329(7471):907–8. doi:10.1136/bmj.329.7471.907.CrossRefPubMedPubMedCentral

40.

Marcovitch H. Use of stimulants for attention deficit hyperactivity disorder: AGAINST. BMJ. 2004;329(7471):908–9. doi:10.1136/bmj.329.7471.908.CrossRefPubMedPubMedCentral

41.

Buitelaar JK, Rothenberger A. Foreword—ADHD in the scientific and political context. Eur Child Adolesc Psychiatry. 2004;13 Suppl 1:I1–6.PubMed

42.

Safer DJ. Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry. 2000;12(1):55–62.CrossRefPubMed

43.

Buitelaar JK. Discussion of attention deficit-hyperactivity disorder (ADHD): facts, opinions and emotions. Ned Tijdschr Geneeskd. 2001;145(31):1485–9. PubMed

44.

Rey JM, Sawyer MG. Are psychostimulant drugs being used appropriately to treat child and adolescent disorders? Br J Psychiatry. 2003;182:284–6. doi:10.1192/bjp.182.4.284.CrossRefPubMed

45.

Accardo P, Blondis TA. What’s all the fuss about Ritalin? J Pediatr. 2001;138(1):6–9. doi:10.1067/mpd.2001.111505.CrossRefPubMed

46.

Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999;104(2):e20. doi:10.1542/peds.104.2.e20.CrossRefPubMed

47.

Barkley RA, Fischer M, Smallish L, Fletcher K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003;111(1):97–109. doi:10.1542/peds.111.1.97.CrossRefPubMed

48.

Bogas S. “Diagnosis du jour?” Understanding attentional deficits can sharpen our treatment strategies. Fam Ther Networker. 1997;21:63–7.

49.

Smelter RW, Rasch BW. Is attention deficit disorder becoming a desired diagnosis? Phi Delta Kappan. 1996;77:429–32.

50.

Sciutto MJ, Eisenberg M. Evaluating the evidence for and against the overdiagnosis of ADHD. J Atten Disord. 2007;11(2):106–13. doi:10.1177/1087054707300094.CrossRefPubMed

51.

Faber A, Kalverdijk LJ, den Berg LT, Hugtenburg JG, Minderaa RB, Tobi H. Parents report on stimulant-treated children in the Netherlands: initiation of treatment and follow-up care. J Child Adolesc Psychopharmacol. 2006;16(4):432–40. doi:10.1089/cap.2006.16.432.CrossRefPubMed

52.

Biederman J, Mick E, Faraone SV, Braaten E, Doyle A, Spencer T, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry. 2002;159(1):36–42. doi:10.1176/appi.ajp.159.1.36.CrossRefPubMed

53.

Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002;5(3):143–54. doi:10.1177/108705470200500302.CrossRefPubMed

54.

Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179–85. doi:10.1542/peds.111.1.179.CrossRefPubMed

55.

Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(1):21–31. doi:10.1097/chi.0b013e31815a56f1.CrossRefPubMed

56.

Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs. 2008;22(3):213–37. doi:10.2165/00023210-200822030-00003.CrossRefPubMed

57.

Cortese S, Konofal E, Yateman N, Mouren MC, Lecendreux M. Sleep and alertness in children with attention-deficit/hyperactivity disorder: a systematic review of the literature. Sleep. 2006;29(4):504–11.PubMed

58.

Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry. 2007;46(2):233–41. doi:10.1097/01.chi.0000246055.76167.0d.CrossRefPubMed

59.

Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil. 2006;27(2):162–74. doi:10.1016/j.ridd.2004.12.004.CrossRefPubMed

60.

Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009. doi:10.1097/CHI.0b013e31817e0ea7.PubMed

61.

Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child. 2005;90(8):801–6. doi:10.1136/adc.2004.056952.CrossRefPubMedPubMedCentral

62.

Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006;45(4):415–21. doi:10.1097/01.chi.0000199026.91699.20.CrossRefPubMed

63.

Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry. 2006;45(5):527–37. doi:10.1097/01.chi.0000205710.01690.d4.CrossRefPubMed

64.

Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(5):520–6. doi:10.1097/01.chi.0000205702.48324.fd.CrossRefPubMed

65.

Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev. 2002;22(8):1107–31.CrossRefPubMed

66.

Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729–40. doi:10.2165/00002018-200326100-00006.CrossRefPubMed

67.

http://www.fda.gov/cder/drug/advisory/adderall.html. Accessed 3 Sep 2008.

68.

Wooltorton E. Suicidal ideation among children taking atomoxetine (Strattera). CMAJ. 2005;173(12):1447.PubMedPubMedCentral

69.

Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47(2):209–18. doi:10.1097/chi.0b013e31815d88b2.CrossRefPubMed

70.

Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med. 2004;34(6):973–82. doi:10.1017/S0033291703001776.CrossRefPubMed

71.

Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380–7. doi:10.1016/j.biopsych.2006.07.032.CrossRefPubMed

72.

Weisler RH, Biederman J, Spencer TJ, Wilens TE, Faraone SV, Chrisman AK, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–39.CrossRefPubMed

Title: Current issues around the pharmacotherapy of ADHD in children and adults
Authors: Willemijn M. Meijer
Adrianne Faber
Els van den Ban
Hilde Tobi
Publication date: 01-10-2009
Publisher: Springer Netherlands
Published in: International Journal of Clinical Pharmacy / Issue 5/2009
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-009-9302-3

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Impact of a computerized physician order entry system on compliance with prescription accuracy requirements

Development of an evidence-based checklist for the detection of drug related problems in type 2 diabetes

Measurement of patient satisfaction with community pharmacy services: a review

Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review

Heart failure exacerbation leading to hospital admission: a cross-sectional study

An evaluation of the integration of standards and guidelines in community pharmacy practices

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage